X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (28) 28
humans (22) 22
male (18) 18
animals (17) 17
immunotherapy (15) 15
oncology (14) 14
ipilimumab (13) 13
mice (13) 13
article (10) 10
cancer (10) 10
medicine, research & experimental (10) 10
prostate cancer (10) 10
cell biology (9) 9
mice, inbred c57bl (9) 9
female (8) 8
middle aged (8) 8
biochemistry & molecular biology (7) 7
aged (6) 6
antibodies, monoclonal - therapeutic use (6) 6
ctla-4 blockade (6) 6
expression (6) 6
immunology (6) 6
prostatic neoplasms - drug therapy (6) 6
prostatic neoplasms - immunology (6) 6
research (6) 6
adverse events (5) 5
antitumor immunity (5) 5
biomarkers (5) 5
chemotherapy (5) 5
ctla-4 antigen - antagonists & inhibitors (5) 5
double-blind (5) 5
health aspects (5) 5
immunotherapy - methods (5) 5
mice, transgenic (5) 5
prostatic neoplasms - pathology (5) 5
survival (5) 5
t-lymphocytes - immunology (5) 5
t-lymphocytes - metabolism (5) 5
antibodies, monoclonal - pharmacology (4) 4
antigens, cd (4) 4
autoimmunity (4) 4
castration (4) 4
cells (4) 4
dendritic cells (4) 4
in-vivo (4) 4
lymphocyte activation (4) 4
melanoma (4) 4
metastasis (4) 4
mice, inbred balb c (4) 4
mice, knockout (4) 4
multidisciplinary sciences (4) 4
nivolumab (4) 4
patients (4) 4
pd-1 blockade (4) 4
t cells (4) 4
therapy (4) 4
toxicity (4) 4
activation (3) 3
adoptive transfer (3) 3
advanced melanoma (3) 3
analysis (3) 3
anti-ctla-4 (3) 3
autoimmune diseases - immunology (3) 3
b7 family (3) 3
biological sciences (3) 3
blockade (3) 3
cd8-positive t-lymphocytes - metabolism (3) 3
cell line, tumor (3) 3
clinical activity (3) 3
clinical trials (3) 3
ctla-4 antigen - metabolism (3) 3
cytokines - biosynthesis (3) 3
drug therapy (3) 3
immune checkpoint (3) 3
immunohistochemistry (3) 3
ipilimumab - adverse effects (3) 3
lymphocytes t (3) 3
open-label (3) 3
programmed cell death 1 receptor - antagonists & inhibitors (3) 3
prostatic neoplasms - genetics (3) 3
prostatic neoplasms - therapy (3) 3
receptor (3) 3
reverse transcriptase polymerase chain reaction (3) 3
signal transduction (3) 3
sipuleucel-t (3) 3
t-lymphocyte subsets - immunology (3) 3
t-lymphocyte subsets - metabolism (3) 3
tumor necrosis factor receptor superfamily, member 9 (3) 3
tumors (3) 3
urology & nephrology (3) 3
4-1bb ligand (2) 2
adverse and side effects (2) 2
aged, 80 and over (2) 2
androgen receptor (2) 2
anti-4-1bb monoclonal-antibodies (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibody (2) 2
antigen (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic agents, immunological - adverse effects (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Medicine, ISSN 1078-8956, 05/2017, Volume 23, Issue 5, pp. 551 - 555
Journal Article
Nature Medicine, ISSN 1078-8956, 12/2018, Volume 24, Issue 12, pp. 1804 - 1808
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2019, Volume 25, Issue 4, pp. 1233 - 1238
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2016, Volume 113, Issue 42, pp. 11919 - 11924
Immune checkpoint therapies, such as ipilimumab, induce dramatic antitumor responses in a subset of patients with advanced malignancies, but they may also... 
Toxicities | T cells | Prostate cancer | CD8 | Ipilimumab | CTLA-4 BLOCKADE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | toxicities | DOCETAXEL | CHEMOTHERAPY | LUNG-CANCER | prostate cancer | ADVANCED MELANOMA | ipilimumab | PROSTATE-CANCER | PHASE-3 TRIAL | DOUBLE-BLIND | NIVOLUMAB | T-Lymphocyte Subsets - immunology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - therapeutic use | CD8-Positive T-Lymphocytes - metabolism | Prostatic Neoplasms - drug therapy | Severity of Illness Index | Prostatic Neoplasms - pathology | Disease Susceptibility | Drug-Related Side Effects and Adverse Reactions - etiology | Treatment Outcome | Ipilimumab - adverse effects | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | T-Lymphocyte Subsets - metabolism | Biomarkers | Lymphocyte Count | Prostatic Neoplasms - complications | CD8-Positive T-Lymphocytes - immunology | Clonal Evolution - immunology | Drug-Related Side Effects and Adverse Reactions - diagnosis | Clinical Trials, Phase II as Topic | Drugs | Complications and side effects | Cell research | CD8 lymphocytes | Physiological aspects | Adverse and side effects | Dosage and administration | Research | Health aspects | Biological Sciences
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2019, Volume 25, Issue 11, pp. 3469 - 3470
Journal Article
Journal Article
Journal Article
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 03/2005, Volume 115, Issue 3, pp. 711 - 717
Journal Article